Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

1.

Accounting for uncertainty in confounder and effect modifier selection when estimating average causal effects in generalized linear models.

Wang C, Dominici F, Parmigiani G, Zigler CM.

Biometrics. 2015 Apr 20. doi: 10.1111/biom.12315. [Epub ahead of print]

PMID:
25899155
2.

BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair.

Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S, Pathania S, McKinney KM, Eaton ML, Kellis M, Hill SJ, Parmigiani G, Proudfoot NJ, Livingston DM.

Mol Cell. 2015 Feb 19;57(4):636-47. doi: 10.1016/j.molcel.2015.01.011.

PMID:
25699710
3.

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM.

Neuro Oncol. 2015 Jan 7. pii: nou345. [Epub ahead of print]

PMID:
25568226
4.

Only three driver gene mutations are required for the development of lung and colorectal cancers.

Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23. doi: 10.1073/pnas.1421839112. Epub 2014 Dec 22.

PMID:
25535351
5.

Differential and limited expression of mutant alleles in multiple myeloma.

Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC.

Blood. 2014 Nov 13;124(20):3110-7. doi: 10.1182/blood-2014-04-569327. Epub 2014 Sep 18.

PMID:
25237203
6.

Misreported family histories and underestimation of risk.

Braun D, Gorfine M, Parmigiani G.

J Clin Oncol. 2014 Nov 10;32(32):3682-3. doi: 10.1200/JCO.2014.57.4848. Epub 2014 Sep 8. No abstract available.

PMID:
25199751
7.

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.

Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y.

Br J Cancer. 2014 Oct 14;111(8):1542-51. doi: 10.1038/bjc.2014.458. Epub 2014 Aug 19.

PMID:
25137022
8.

Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis.

Zhao SD, Parmigiani G, Huttenhower C, Waldron L.

Bioinformatics. 2014 Nov 1;30(21):3062-9. doi: 10.1093/bioinformatics/btu488. Epub 2014 Jul 23.

PMID:
25061068
9.

Cross-study validation for the assessment of prediction algorithms.

Bernau C, Riester M, Boulesteix AL, Parmigiani G, Huttenhower C, Waldron L, Trippa L.

Bioinformatics. 2014 Jun 15;30(12):i105-12. doi: 10.1093/bioinformatics/btu279.

10.

Recent BRCAPRO upgrades significantly improve calibration.

Mazzola E, Chipman J, Cheng SC, Parmigiani G.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1689-95. doi: 10.1158/1055-9965.EPI-13-1364. Epub 2014 Jun 2.

PMID:
24891549
11.

Completing the results of the 2013 Boston marathon.

Hammerling D, Cefalu M, Cisewski J, Dominici F, Parmigiani G, Paulson C, Smith RL.

PLoS One. 2014 Apr 11;9(4):e93800. doi: 10.1371/journal.pone.0093800. eCollection 2014.

12.

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju048. doi: 10.1093/jnci/dju048.

13.

Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer.

Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, Wang XV, Ahmadifar M, Tyekucheva S, Bernau C, Risch T, Ganzfried BF, Huttenhower C, Birrer M, Parmigiani G.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju049. doi: 10.1093/jnci/dju049. Review.

14.

Frailty Models for Familial Risk with Application to Breast Cancer.

Gorfine M, Hsu L, Parmigiani G.

J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215.

15.

Modular network construction using eQTL data: an analysis of computational costs and benefits.

Ho YY, Cope LM, Parmigiani G.

Front Genet. 2014 Feb 26;5:40. doi: 10.3389/fgene.2014.00040. eCollection 2014.

16.

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.

Tomasetti C, Demetri GD, Parmigiani G.

F1000Res. 2013 Jul 9;2:152. doi: 10.12688/f1000research.2-152.v1. eCollection 2013.

17.

Mental capacity in patients involuntarily or voluntarily receiving psychiatric treatment for an acute mental disorder.

Mandarelli G, Tarsitani L, Parmigiani G, Polselli GM, Frati P, Biondi M, Ferracuti S.

J Forensic Sci. 2014 Jul;59(4):1002-7. doi: 10.1111/1556-4029.12420. Epub 2014 Feb 6.

PMID:
24502678
18.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.

Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.

19.

Reclassification of predictions for uncovering subgroup specific improvement.

Biswas S, Arun B, Parmigiani G.

Stat Med. 2014 May 20;33(11):1914-27. doi: 10.1002/sim.6077. Epub 2013 Dec 18.

PMID:
24353130
20.

Statistical tools and R software for cancer driver probabilities.

Parmigiani G, Boca S, Ding J, Trippa L.

Methods Mol Biol. 2014;1101:113-34. doi: 10.1007/978-1-62703-721-1_7.

PMID:
24233780
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk